RA
ATRS

Royce & Associates’s Antares Pharma, Inc. ATRS Stock Holding History

Royce & Associates’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-406,900
Closed -$684K – 1116
2016
Q3 		$684K Hold
406,900
– – ﹤0.01% 972
2016
Q2 		$427K Hold
406,900
– – ﹤0.01% 1003
2016
Q1 		$354K Buy
406,900
+309,616
+318% +$300K ﹤0.01% 1017
2015
Q4 		$118K Buy
+97,284
New +$135K ﹤0.01% 1092

Other funds holding ATRS

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Royce & Associates's ATRS Position: Q4 2016 in Review

Royce & Associates sold out of Antares Pharma, Inc. (ATRS) in Q4 2016, closing a stake of 406,900 shares — an estimated $684K sold.

Royce & Associates first reported a position in ATRS in Q4 2015 and held it in 4 quarters. The position peaked at $684K in Q3 2016. 71 funds tracked by Wall St. Rank hold ATRS as of Q4 2016.

  • Royce & Associates reported no remaining Antares Pharma, Inc. position as of Q4 2016 after selling out during the quarter.
  • Royce & Associates sold 406,900 Antares Pharma, Inc. shares in Q4 2016, an estimated $684K.
  • Royce & Associates first reported a position in Antares Pharma, Inc. in Q4 2015 and held it in 4 quarters.
  • Royce & Associates's Antares Pharma, Inc. position peaked at $684K in Q3 2016.
  • 71 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2016.

Based on Royce & Associates's 13F filing for Q4 2016, filed 10 Feb 2017.